Memphasys (ASX:MEM) Forward PE Ratio: 0.00 (As of Jul. 12, 2026)


What is Memphasys Forward PE Ratio?

Memphasys ASX:MEM -12.50% Forward PE Ratio is 0.00 as of Jul. 12, 2026. The stock has 5 warning signs investors should review. Among 392 Medical Devices & Instruments companies, Memphasys ranks worse than 255101.79% on this metric.

Memphasys's Forward PE Ratio for today is 0.00.

Memphasys's PE Ratio without NRI for today is 0.00.

Memphasys's PE Ratio (TTM) for today is 0.00.

Memphasys  (ASX:MEM) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Memphasys Forward PE Ratio Related Terms

Memphasys Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Memphasys's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Memphasys Forward PE Ratio Chart

Memphasys Annual Data
Trend
Forward PE Ratio

Memphasys Semi-Annual Data
Forward PE Ratio

ASX:MEM vs ABT, SYK, MDT: Forward PE Ratio Comparison

For the Medical Devices subindustry, Memphasys's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Memphasys Forward PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Memphasys's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Memphasys's Forward PE Ratio falls into.


Memphasys Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 0.00 mean?
Memphasys (ASX:MEM) has a Forward PE Ratio of 0.00 as of Jul. 12, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Memphasys and its competitors. According to the industry distribution chart, Memphasys ranks #999999 out of 392 companies in the Medical Devices & Instruments industry.
Is Memphasys' Forward PE Ratio too high?
Memphasys' current Forward PE Ratio is 0.00. Based on the distribution chart, Memphasys ranks #999999 out of 392 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Memphasys' Forward PE Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Memphasys ranks #999999 out of 392 companies for Forward PE Ratio. This places Memphasys in the lower half of its industry. The industry median Forward PE Ratio is 19.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.14, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Memphasys and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Memphasys's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Memphasys stock overvalued right now?
Memphasys (ASX:MEM) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Memphasys (ASX:MEM), the current Forward PE Ratio is 0.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Memphasys Business Description

Other Exchanges IG7:Germany
Address 34-36 Richmond Road, Level 1, Homebush West, Sydney, NSW, AUS, 2140
Memphasys Ltd is an Australian reproductive biotechnology company developing and commercializing novel reproduction and fertility solutions for humans and animals. The products in its development pipeline include a range of devices, media, and in vitro diagnostic solutions. The company is currently focused on the commercialisation of its patented Felix System, a novel bio-separation technology for assisted reproduction, designed to revolutionise sperm separation in assisted reproductive technology (ART) by providing a rapid, gentle, and automated process. The group has only one operating segment, being Reproductive Technologies, the assets and liabilities of which are located in Australia.